Historically, pancreatic islet beta cells have been viewed as principal regulators of glycemia,
with type 2 diabetes (T2D) resulting when insulin secretion fails to compensate for …

The introduction of insulin in the treatment of juvenile-onset, now type 1, diabetes mellitus
transformed a rapidly fatal disease into a chronic degenerative one. During the insulin …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Background The effectiveness of real-time continuous glucose monitoring (rtCGM) in
avoidance of hypoglycaemia among high-risk individuals with type 1 diabetes treated with …

Impaired awareness of hypoglycaemia (IAH) is a major risk for severe hypoglycaemia in
insulin treatment of type 1 diabetes (T1D). To explore the hypothesis that unhelpful health …

Background Hypoglycaemia unawareness and severe hypoglycaemia can increase fear of
hypoglycaemia and the risk of subsequent hypoglycaemic events. We aimed to assess the …

BACKGROUND We investigated residual β cell function in Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions and Complications …

Objective: To evaluate safety and effectiveness of MiniMed™ 670G hybrid closed loop
(HCL) in comparison with continuous subcutaneous insulin infusion (CSII) therapy for 6 …

Impaired awareness of hypoglycemia (IAH) is a reduction in the ability to recognize low
blood glucose levels that would otherwise prompt an appropriate corrective therapy …

Technological advances have made the artificial pancreas a reality. This has the potential to
improve the lives of individuals with Type 1 diabetes by reducing the risk of hypoglycaemia …